China's drug administrator approved Sinocelltech (SHA:688520) subsidiary Beijing Sinocell Biotechnology Group's clinical trial for its SCT640C injection for rheumatoid arthritis, according to a Friday filing with the Shanghai bourse.
China's drug administrator approved Sinocelltech (SHA:688520) subsidiary Beijing Sinocell Biotechnology Group's clinical trial for its SCT640C injection for rheumatoid arthritis, according to a Friday filing with the Shanghai bourse.
Comments